Market Place
Sourcing Support
AstraZeneca Closes Acquisition of Amolyt Pharma
15 Jul 2024 //
GLOBENEWSWIRE
Amolyt Abstracts Accepted At GRS Congress, ECE And ENDO Conferences
07 May 2024 //
GLOBENEWSWIRE
Amolyt`s Eneboparatide Gets FDA Fast Track For Hypoparathyroidism
02 May 2024 //
GLOBENEWSWIRE
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
15 Mar 2024 //
REUTERS
Amolyt Named ˜Biotech Company of the Year™ at the LSX European Lifestars Awards
16 Nov 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients
16 Oct 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Two Poster Presentations at ASBMR
03 Oct 2023 //
GLOBENEWSWIRE
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide
27 Sep 2023 //
GLOBENEWSWIRE
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide
07 Jun 2023 //
GLOBENEWSWIRE
Amolyt Announces Initiation of Phase 1 Clinical Trial of Peptide GHRA, AZP-3813
05 Jun 2023 //
GLOBENEWSWIRE
Amolyt Pharma Launches Public Awareness Campaign
01 Jun 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Oral Presentation at the 25th ECE 2023
11 May 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
05 May 2023 //
PHARRMIWEB
Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide
02 May 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA
24 Jan 2023 //
GLOBENEWSWIRE
Amolyt hauls in €130M round to fund PhIII trial of hypoparathyroidism drug
06 Jan 2023 //
ENDPTS
Amolyt Pharma Announces $138 M Series C Financing led by Sofinnova Partners
06 Jan 2023 //
GLOBENEWSWIRE
Amolyt Announces Positive Safety and Efficacy Results Pha2a Trial of AZP-3601
12 Oct 2022 //
GLOBENEWSWIRE
Amolyt Pharma Announces +ve Efficacy and Safety Data fromPh 2a Study of AZP-3601
12 Sep 2022 //
GLOBENEWSWIRE
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Hypoparathyroidism
07 Sep 2022 //
GLOBENEWSWIRE
Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601
01 Sep 2022 //
GLOBENEWSWIRE
Amolyt Pharma Strengthens Leadership Team; Appoints Mark Sumeray as CMO
29 Jun 2022 //
GLOBENEWSWIRE
Amolyt Pharma Announces Positive Results from PIIa Trial of AZP-3601
01 Jun 2022 //
GLOBENEWSWIRE
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
16 May 2022 //
GLOBENEWSWIRE
Amolyt Pharma says US IND Clearance for the Ongoing Trial of AZP-3601
17 Mar 2022 //
GLOBENEWSWIRE
EC Grants ODD to Amolyt Pharma`s AZP-3601 for Hypoparathyroidism
01 Mar 2022 //
GLOBENEWSWIRE
Amolyt Pharma to Participate at Three Upcoming Investor Conferences
11 Feb 2022 //
GLOBENEWSWIRE
Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601
01 Oct 2021 //
GLOBENEWSWIRE
Amolyt Pharma Announces $80 Million Series B Financing
16 Sep 2021 //
GLOBENEWSWIRE
Amolyt Pharma announces USD 80 million Series B financing
16 Sep 2021 //
GLOBENEWSWIRE
Novo-backed Amolyt Pharma snags $80M for endocrine pipeline
16 Sep 2021 //
FIERCEBIOTECH
Amolyt Exercises Option to License Optimized Acromegaly Drug from PeptiDream
09 Sep 2021 //
BIOSPACE
Amolyt Pharma Announces Appointment of Two Directors
08 Jul 2021 //
GLOBENEWSWIRE
Amolyt Pharma Announces Hiring of Louis J. Arcudi III as Chief Financial Officer
06 Jul 2021 //
GLOBENEWSWIRE
Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone
18 May 2021 //
GLOBENEWSWIRE
Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone
22 Mar 2021 //
GLOBENEWSWIRE
